Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer
The combination of TT with ICIs offers a significant advantage in terms of PFS for patients with advanced mCRC, accompanied by a favorable safety profile. These findings underscore the benefits of combination therapy in this setting, warranting further investigation in larger prospective clinical trials.
Authors
- Suyao Li
- Xuemin Yao (ORCID: https://orcid.org/0009-0007-8214-1358)
- Dapeng Li (ORCID: https://orcid.org/0000-0002-0749-0001)
- P. H. Wang (ORCID: https://orcid.org/0009-0009-8779-1258)
- Jing Wang (ORCID: https://orcid.org/0000-0002-5398-0802)
- Lu Sun (ORCID: https://orcid.org/0000-0003-2393-241X)
- Jie Yan (ORCID: https://orcid.org/0000-0002-2326-977X)
- Wei-Li Cheng
- Yongling Yu
- Jinghao Jia
Institutions
- North China University of Science and Technology (CN)
- Qinhuangdao Second Hospital (CN)
- Tangshan People's Hospital (CN)
- North China University of Science and Technology Affiliated Hospital (CN)
- First Hospital of Qinhuangdao (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.4251/wjgo.v17.i5.105027
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00